These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 26882436)

  • 1. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
    Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
    Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
    J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.
    Karnes HE; Duncavage EJ; Bernadt CT
    Cancer Cytopathol; 2014 Feb; 122(2):104-13. PubMed ID: 24227699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung.
    Stigt JA; 'tHart NA; Knol AJ; Uil SM; Groen HJ
    J Thorac Oncol; 2013 Aug; 8(8):1012-8. PubMed ID: 23807543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
    Sánchez-Font A; Chalela R; Martín-Ontiyuelo C; Albero-González R; Dalmases A; Longarón R; Alonso-Espinaco V; Curull V; Bellosillo B; Pijuan L
    Cancer Cytopathol; 2018 Oct; 126(10):860-871. PubMed ID: 30291816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas.
    Schneider F; Smith MA; Lane MC; Pantanowitz L; Dacic S; Ohori NP
    Am J Clin Pathol; 2015 Feb; 143(2):193-200; quiz 306. PubMed ID: 25596245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
    Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
    Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
    Lewandowska MA; Jóźwicki W; Jochymski C; Kowalewski J
    Oncol Rep; 2013 Sep; 30(3):1045-52. PubMed ID: 23817662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
    Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
    Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
    Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens.
    Wu W; Huang Y; Guo J; Xie X; Li H; Cao Z; Wei H; Wu C
    Cancer Cytopathol; 2020 Aug; 128(8):545-552. PubMed ID: 32286726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
    Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
    Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.